William G. Woods
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William G. Woods has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Mendel Tuchman
Affiliations of authors: Department of Economics, McGill University, Montreal, Quebec (LS); AFLAC Cancer Center, Emory University/Children's Healthcare of Atlanta, GA (WGW); Hôpital Sainte-Justine, University of Montreal, Quebec (MB); University of Minnesota, Department of Pediatrics, Minneapolis (LLR); Children's National Medical Center, The George Washington University, Washington, DC (MT); Centre Universitaire de Santé de L'Estrie, Sherbrooke, Quebec (BL)
5 shared publicationsBernard Lemieux
Affiliations of authors: Department of Economics, McGill University, Montreal, Quebec (LS); AFLAC Cancer Center, Emory University/Children's Healthcare of Atlanta, GA (WGW); Hôpital Sainte-Justine, University of Montreal, Quebec (MB); University of Minnesota, Department of Pediatrics, Minneapolis (LLR); Children's National Medical Center, The George Washington University, Washington, DC (MT); Centre Universitaire de Santé de L'Estrie, Sherbrooke, Quebec (BL)
4 shared publicationsLeslie L. Robison
Affiliations of authors: Department of Economics, McGill University, Montreal, Quebec (LS); AFLAC Cancer Center, Emory University/Children's Healthcare of Atlanta, GA (WGW); Hôpital Sainte-Justine, University of Montreal, Quebec (MB); University of Minnesota, Department of Pediatrics, Minneapolis (LLR); Children's National Medical Center, The George Washington University, Washington, DC (MT); Centre Universitaire de Santé de L'Estrie, Sherbrooke, Quebec (BL)
3 shared publicationsTodd A. Alonzo
Children's Oncology Group (COG) Statistics Center Arcadia California
3 shared publicationsBeverly J. Lange
2 shared publicationsDiane C. Arthur
2 shared publications
Latest Publications
- Open Access
- 5 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4) , pkab042
Screening for Neuroblastoma Using Urinary Catecholamines: The End of the Story
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, with a peak incidence at birth. About 40% of children are diagnosed in the first year of life, and by 6 years of age, more than 90% of children will have presented with the disease. Unlike cancers in adults, where many common malignancies can be preclinically detected, including the 4 most prevalent cancers—lung, colon, prostate, and breast—no pediatric cancer was deemed easily detectable by screening. The 1 exception was NB because it has been known for decades that 90% of patients presenting clinically excrete elevated catecholamine metabolites in their urine. Furthermore, if children present with NB at a young age—specifically, under 18 months of age—the prognosis is outstanding, with about 90% of cases cured. Based on these facts, Sawada and Japanese colleagues pioneered NB screening programs in the 1970s ( 1), with early results suggesting that overall survival in the children screened improved. Unfortunately, survival can look artificially increased if screening programs diagnose patients whose tumors would have spontaneously regressed, a known phenomenon in NB. One must determine population-based mortality to determine true efficacy of any such intervention.
- 5 May 2021
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (4) , pkab042
Open AccessScreening for Neuroblastoma Using Urinary Catecholamines: The End of the Story
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, with a peak incidence at birth. About 40% of children are diagnosed in the first year of life, and by 6 years of age, more than 90% of children will have presented with the disease. Unlike cancers in adults, where many common malignancies can be preclinically detected, including the 4 most prevalent cancers—lung, colon, prostate, and breast—no pediatric cancer was deemed easily detectable by screening. The 1 exception was NB because it has been known for decades that 90% of patients presenting clinically excrete elevated catecholamine metabolites in their urine. Furthermore, if children present with NB at a young age—specifically, under 18 months of age—the prognosis is outstanding, with about 90% of cases cured. Based on these facts, Sawada and Japanese colleagues pioneered NB screening programs in the 1970s ( 1), with early results suggesting that overall survival in the children screened improved. Unfortunately, survival can look artificially increased if screening programs diagnose patients whose tumors would have spontaneously regressed, a known phenomenon in NB. One must determine population-based mortality to determine true efficacy of any such intervention.
- Open Access
- 7 December 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (Suppl_1) , 883
Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group
There remains uncertainty regarding the optimal treatment for mixed phenotype acute leukemia (MPAL), an uncommon leukemia that represents ~3% of de novo acuteleukemia. Because of the dearth of clinical trials, varying approaches are employed: acute lymphoblastic leukemia (ALL) regimens as well as more intensive acute myeloid leukemia (AML) and hybrid therapies. The evolution in the prevailing diagnostic criteria from the EGIL classification to the more narrowly defined WHO2008 and WHO2016 criteria has made the existing literature difficult to interpret. Increasing insight into the molecular heterogeneity of MPAL adds further complexity. Recently published studies (retrospective clinical case series), however, are beginning to suggest that ALL therapy may be the most appropriate form of initial therapy for MPAL. To further assess the efficacy of ALL therapy for pediatric MPAL, we reviewed the Children's Oncology Group (COG) experience. Possible MPAL cases were identified through the ALL biology studies (both AALL03B1 and AALL08B1 were open to MPAL) and from AAML0531, the phase 3 trial for de novo AML (patients enrolled on this trial subsequently found to have MPAL were taken off study). All identified cases were reviewed centrally. In cases where the original flow cytometry testing was inadequate to establish the diagnosis, flow cytometry was repeated with an expanded antibody panel using banked diagnostic specimens. Only cases meeting WHO2016 criteria were retained. Patients were treated per physician discretion and not on a therapeutic clinical trial. Supplemental data on treatment and outcomes were collected. From the study databases, 97 potential MPAL cases were identified; of these, 54 cases (56%) were confirmed to be MPAL via central review. Patients were diagnosed between 2003 and 2016. The majority of patients were <10 years of age and B/Myeloid MPAL (B/My) was the most common phenotype. Fewer than a third of patients presented with hyperleukocytosis, adverse recurrent cytogenetics, or central nervous system involvement (Table 1). In the cohort, 38 patients (70%) received ALL induction therapy, 12 (22%) AML induction, and 3 hybrid induction; 14 (28%) patients received hematopoietic stem cell transplantation (HSCT). The CR rate was 71.1% [27/38], 66.7% (8/12) and 100% (3/3) in patients receiving ALL, AML and hybrid induction, respectively (p=0.761). CR was achieved in 78.8% of B/My cases [26/33], 68.4% T/My cases [13/19], and no B/T cases (0/2, p=0.074). Treatment became more heterogeneous further into therapy due to varying incorporation of ALL, AML and hybrid elements and the varying use of HSCT. Three-year EFS was 65±17% in patients started on ALL therapy and 53±26% in patients started on AML therapy (p=0.169, Fig. 1A); 3-year OS was 79±15% and 60±27% respectively (p=0.510, Fig. 1B). SCT was not associated with a difference in EFS (p=0.935) or OS (p=0.726). In 20 patients receiving ALL therapy alone without SCT, 3-year EFS was 59±22% and OS 79±18%. This series represents a large cohort of centrally-reviewed pediatric MPAL cases diagnosed according to the most recent WHO2016 criteria and treated with COG-style chemotherapy. Our results add to the growing body of literature suggesting that ALL regimens may be effective for pediatric MPAL. It also suggests, however, that induction failure and relapse are still relatively common with ALL therapy and that alternative forms of treatment are necessary for some. The limited size of the sample and its heterogeneity preclude any conclusions regarding the relative efficacy of AML therapy and role for HSCT. Given the greater morbidity and mortality associated with these forms of therapy, consideration should be given to reserving their use for patients with a suboptimal response to ALL therapy. Continued variability in accurately diagnosing and treating MPAL as seen here also underscores the necessity of well-delineated clinical trials with integrated central review to advance MPAL therapy. Our results therefore further support the basis for the first-ever prospective evaluation of high risk ALL therapy for pediatric MPAL in a trial now being planned within the COG. In this trial, minimal residual disease testing with multiparameter flow cytometry will be employed to identify patients responding well to ALL therapy versus those who may benefit from more intensive AML therapy and transplantation.
- 7 December 2017
- Published by American Society of Hematology in Blood
- Vol. 130 (Suppl_1) , 883
Open AccessEfficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group
There remains uncertainty regarding the optimal treatment for mixed phenotype acute leukemia (MPAL), an uncommon leukemia that represents ~3% of de novo acuteleukemia. Because of the dearth of clinical trials, varying approaches are employed: acute lymphoblastic leukemia (ALL) regimens as well as more intensive acute myeloid leukemia (AML) and hybrid therapies. The evolution in the prevailing diagnostic criteria from the EGIL classification to the more narrowly defined WHO2008 and WHO2016 criteria has made the existing literature difficult to interpret. Increasing insight into the molecular heterogeneity of MPAL adds further complexity. Recently published studies (retrospective clinical case series), however, are beginning to suggest that ALL therapy may be the most appropriate form of initial therapy for MPAL. To further assess the efficacy of ALL therapy for pediatric MPAL, we reviewed the Children's Oncology Group (COG) experience. Possible MPAL cases were identified through the ALL biology studies (both AALL03B1 and AALL08B1 were open to MPAL) and from AAML0531, the phase 3 trial for de novo AML (patients enrolled on this trial subsequently found to have MPAL were taken off study). All identified cases were reviewed centrally. In cases where the original flow cytometry testing was inadequate to establish the diagnosis, flow cytometry was repeated with an expanded antibody panel using banked diagnostic specimens. Only cases meeting WHO2016 criteria were retained. Patients were treated per physician discretion and not on a therapeutic clinical trial. Supplemental data on treatment and outcomes were collected. From the study databases, 97 potential MPAL cases were identified; of these, 54 cases (56%) were confirmed to be MPAL via central review. Patients were diagnosed between 2003 and 2016. The majority of patients were <10 years of age and B/Myeloid MPAL (B/My) was the most common phenotype. Fewer than a third of patients presented with hyperleukocytosis, adverse recurrent cytogenetics, or central nervous system involvement (Table 1). In the cohort, 38 patients (70%) received ALL induction therapy, 12 (22%) AML induction, and 3 hybrid induction; 14 (28%) patients received hematopoietic stem cell transplantation (HSCT). The CR rate was 71.1% [27/38], 66.7% (8/12) and 100% (3/3) in patients receiving ALL, AML and hybrid induction, respectively (p=0.761). CR was achieved in 78.8% of B/My cases [26/33], 68.4% T/My cases [13/19], and no B/T cases (0/2, p=0.074). Treatment became more heterogeneous further into therapy due to varying incorporation of ALL, AML and hybrid elements and the varying use of HSCT. Three-year EFS was 65±17% in patients started on ALL therapy and 53±26% in patients started on AML therapy (p=0.169, Fig. 1A); 3-year OS was 79±15% and 60±27% respectively (p=0.510, Fig. 1B). SCT was not associated with a difference in EFS (p=0.935) or OS (p=0.726). In 20 patients receiving ALL therapy alone without SCT, 3-year EFS was 59±22% and OS 79±18%. This series represents a large cohort of centrally-reviewed pediatric MPAL cases diagnosed according to the most recent WHO2016 criteria and treated with COG-style chemotherapy. Our results add to the growing body of literature suggesting that ALL regimens may be effective for pediatric MPAL. It also suggests, however, that induction failure and relapse are still relatively common with ALL therapy and that alternative forms of treatment are necessary for some. The limited size of the sample and its heterogeneity preclude any conclusions regarding the relative efficacy of AML therapy and role for HSCT. Given the greater morbidity and mortality associated with these forms of therapy, consideration should be given to reserving their use for patients with a suboptimal response to ALL therapy. Continued variability in accurately diagnosing and treating MPAL as seen here also underscores the necessity of well-delineated clinical trials with integrated central review to advance MPAL therapy. Our results therefore further support the basis for the first-ever prospective evaluation of high risk ALL therapy for pediatric MPAL in a trial now being planned within the COG. In this trial, minimal residual disease testing with multiparameter flow cytometry will be employed to identify patients responding well to ALL therapy versus those who may benefit from more intensive AML therapy and transplantation.
- 18 June 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (8)
Robert J. Arceci, MD, PhD, 1950-2015
- 18 June 2015
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (8)
Robert J. Arceci, MD, PhD, 1950-2015
- Open Access
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials
BACKGROUND: A retrospective meta‐analysis of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) was performed to determine if differences in outcome exist following treatment on pediatric versus adult oncology treatment regimens.METHODS: Outcomes were compared of 517 AYAs with AML aged 16 to 21 years who were treated on Children's Oncology Group (COG), Cancer and Leukemia Group B (CALGB), and Southwest Oncology Group (SWOG) frontline AML trials from 1986 to 2008.RESULTS: There was a significant age difference between AYA cohorts in the COG, CALGB, and SWOG trials (median, 17.2 versus 20.1 versus 19.8 years, P < .001). The 10‐year event‐free survival of the COG cohort was superior to the combined adult cohorts (38% ± 6% versus 23% ± 6%, log‐rank P = .006) as was overall survival (45% ± 6% versus 34% ± 7%), with a 10‐year estimate comparison of P = .026. However, the younger age of the COG cohort is confounding, with all patients aged 16 to 18 years doing better than those aged 19 to 21 years. Although the 10‐year relapse rate was lower for the COG patients (29% ± 6% versus 57% ± 8%, Gray's P < .001), this was offset by a higher postremission treatment‐related mortality of 26% ± 6% versus 12% ± 6% (Gray's P < .001). Significant improvements in 10‐year event‐free survival and overall survival were observed for the entire cohort in later studies.CONCLUSIONS: Patients treated on pediatric trials had better outcomes than those treated on adult trials, but age is a major confounding variable, making it difficult to compare outcomes by cooperative group. Cancer 2013;119:4170–4179. © 2013 American Cancer Society.
Open AccessOutcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials
BACKGROUND: A retrospective meta‐analysis of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) was performed to determine if differences in outcome exist following treatment on pediatric versus adult oncology treatment regimens.METHODS: Outcomes were compared of 517 AYAs with AML aged 16 to 21 years who were treated on Children's Oncology Group (COG), Cancer and Leukemia Group B (CALGB), and Southwest Oncology Group (SWOG) frontline AML trials from 1986 to 2008.RESULTS: There was a significant age difference between AYA cohorts in the COG, CALGB, and SWOG trials (median, 17.2 versus 20.1 versus 19.8 years, P < .001). The 10‐year event‐free survival of the COG cohort was superior to the combined adult cohorts (38% ± 6% versus 23% ± 6%, log‐rank P = .006) as was overall survival (45% ± 6% versus 34% ± 7%), with a 10‐year estimate comparison of P = .026. However, the younger age of the COG cohort is confounding, with all patients aged 16 to 18 years doing better than those aged 19 to 21 years. Although the 10‐year relapse rate was lower for the COG patients (29% ± 6% versus 57% ± 8%, Gray's P < .001), this was offset by a higher postremission treatment‐related mortality of 26% ± 6% versus 12% ± 6% (Gray's P < .001). Significant improvements in 10‐year event‐free survival and overall survival were observed for the entire cohort in later studies.CONCLUSIONS: Patients treated on pediatric trials had better outcomes than those treated on adult trials, but age is a major confounding variable, making it difficult to compare outcomes by cooperative group. Cancer 2013;119:4170–4179. © 2013 American Cancer Society.
- Open Access
- 1 November 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (31) , 4929-4932
Incidence of Neuroblastoma After a Screening Program
Purpose: A significant increase in the incidence of neuroblastoma occurred among a 5-year birth cohort (May 1989 to April 1994) during an active urinary screening program for its early detection. We examined the postscreening incidence of neuroblastoma in the subsequent 5-year birth cohort (May 1994 to April 1999), with follow-up to 2002, to determine whether the incidence remained increased. Patients and Methods: We reviewed institutional records of patients diagnosed with neuroblastoma during the period from 1994 to 2002 who were born in 1994 to 1999 in the province of Quebec, as well as in the state of Minnesota and the province of Ontario, regions that had served as controls during the screening interval. We calculated and compared incidence rates during the 1994 to 2002 time period. Results: For the 5-year birth cohort as a whole, the rate of newly diagnosed neuroblastoma was higher in Quebec than in the control populations of Minnesota and Ontario (standardized incidence ratio, 1.34; 95% CI, 1.03 to 1.70). However, in years 4 and 5 of the interval, population-based incidence declined to the same levels as those seen in the control areas. Conclusion: The institution of a urinary screening program for neuroblastoma led to increased awareness of the diagnosis and an elevated rate of diagnosis even after the completion of the screening evaluation. However, this halo effect was transient, with diagnostic rates subsequently decreasing within the range seen in control populations.
- 1 November 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (31) , 4929-4932
Open AccessIncidence of Neuroblastoma After a Screening Program
Purpose: A significant increase in the incidence of neuroblastoma occurred among a 5-year birth cohort (May 1989 to April 1994) during an active urinary screening program for its early detection. We examined the postscreening incidence of neuroblastoma in the subsequent 5-year birth cohort (May 1994 to April 1999), with follow-up to 2002, to determine whether the incidence remained increased. Patients and Methods: We reviewed institutional records of patients diagnosed with neuroblastoma during the period from 1994 to 2002 who were born in 1994 to 1999 in the province of Quebec, as well as in the state of Minnesota and the province of Ontario, regions that had served as controls during the screening interval. We calculated and compared incidence rates during the 1994 to 2002 time period. Results: For the 5-year birth cohort as a whole, the rate of newly diagnosed neuroblastoma was higher in Quebec than in the control populations of Minnesota and Ontario (standardized incidence ratio, 1.34; 95% CI, 1.03 to 1.70). However, in years 4 and 5 of the interval, population-based incidence declined to the same levels as those seen in the control areas. Conclusion: The institution of a urinary screening program for neuroblastoma led to increased awareness of the diagnosis and an elevated rate of diagnosis even after the completion of the screening evaluation. However, this halo effect was transient, with diagnostic rates subsequently decreasing within the range seen in control populations.
- 15 May 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (6)
The American Society of Pediatric Hematology/Oncology (ASPHO) 2006 distinguished career award goes to W. Archie Bleyer, MD
- 15 May 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (6)
The American Society of Pediatric Hematology/Oncology (ASPHO) 2006 distinguished career award goes to W. Archie Bleyer, MD
- 1 May 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (5) , 565-569
Curing childhood acute myeloid leukemia (AML) at the half-way point: Promises to keep and miles to go before we sleep
Childhood and adolescent acute myeloid leukemia (AML) is traditionally one of the hardest childhood cancers to successfully treat and had an overall survival well under 10% in the 1960s. Initial progress was made by three major events: (1) active chemotherapeutic agents were identified which led to remissions for the first time in this disease; (2) cooperative groups were instituted leading to important clinical trials; and (3) several single institutions began experimenting with the role of allogeneic matched sibling donor (MSD) BMT as effective intensification. Over the last 25 years, the cure rate has improved from <20% to 50% or higher. Most of the clinical research during this time of great advancement focused on two major themes: (1) the role of aggressive induction therapy in not only improving CR rates but in post-remission outcomes; and (2) the role of aggressive post-remission therapy in further improving survival, with an emphasis on high-dose Ara C-based chemotherapy, BMT, and supportive care. But we have "miles to go before we sleep." Some of the challenges that will lead to ongoing reduction of population-based mortality for AML through young adulthood include: (1) improving access of adolescents to pediatric AML therapy; (2) stratification by prognostic factors; (3) individualized therapy based on individual genetics and leukemia cell biology; (4) and the use of novel therapies including targeted immuno-conjugates and "small molecules" which disrupt abnormal signal transduction pathways. This brief review looks at both the advances over the last three decades as well as discusses the challenges moving forward for ultimately curing all children with this disease.
- 1 May 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (5) , 565-569
Curing childhood acute myeloid leukemia (AML) at the half-way point: Promises to keep and miles to go before we sleep
Childhood and adolescent acute myeloid leukemia (AML) is traditionally one of the hardest childhood cancers to successfully treat and had an overall survival well under 10% in the 1960s. Initial progress was made by three major events: (1) active chemotherapeutic agents were identified which led to remissions for the first time in this disease; (2) cooperative groups were instituted leading to important clinical trials; and (3) several single institutions began experimenting with the role of allogeneic matched sibling donor (MSD) BMT as effective intensification. Over the last 25 years, the cure rate has improved from <20% to 50% or higher. Most of the clinical research during this time of great advancement focused on two major themes: (1) the role of aggressive induction therapy in not only improving CR rates but in post-remission outcomes; and (2) the role of aggressive post-remission therapy in further improving survival, with an emphasis on high-dose Ara C-based chemotherapy, BMT, and supportive care. But we have "miles to go before we sleep." Some of the challenges that will lead to ongoing reduction of population-based mortality for AML through young adulthood include: (1) improving access of adolescents to pediatric AML therapy; (2) stratification by prognostic factors; (3) individualized therapy based on individual genetics and leukemia cell biology; (4) and the use of novel therapies including targeted immuno-conjugates and "small molecules" which disrupt abnormal signal transduction pathways. This brief review looks at both the advances over the last three decades as well as discusses the challenges moving forward for ultimately curing all children with this disease.
- 26 April 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 48 (2) , 247
Neuroblastomas that might benefit from mass screening at 6 months of age in Japan—response
- 26 April 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 48 (2) , 247
Neuroblastomas that might benefit from mass screening at 6 months of age in Japan—response
- Open Access
- 3 August 2005
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (15) , 1118-1124
Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening
Background: Well-designed evaluations of health services are frequently made today. However, the extent of the evaluations' benefits and costs is not well documented, creating uncertainty whether their use is optimal from society's perspective. We examined these costs and benefits using data from one well-designed evaluation, the Quebec Neuroblastoma Screening Project (QNSP). It screened most Quebec newborns between 1989 and 1994 for neuroblastoma. As previously reported, the screening did not reduce neuroblastoma mortality and caused adverse health effects. Methods: We compared the cost of doing the QNSP with its benefits. Had the QNSP not been undertaken, neuroblastoma screening would have been implemented throughout North America. We assume that screening would have started in 1989 and ended in 2002. The QNSP's benefits include the health costs and adverse health effects averted by not using ineffective screening during those 14 years. In our calculations we used neuroblastoma incidence data for the QNSP and for Ontario where there was no screening, detailed data describing the health services used by the patients, and Quebec cost data for those services. Results: The QNSP cost $8.77 million (2002 US dollars). By not implementing similar screening programs between 1989 and 2002, the United States and Canada avoided $574.1 million in health costs, the unnecessary treatment of 9223 children, and false-positive findings for 5003 children screened. Conclusions: The health care costs and adverse health effects averted by the QNSP justify its costs. These results show that well-designed evaluations can yield—at least sometimes—benefits substantially greater than their high costs. This raises an important policy issue: are these evaluations now being under- or over used?
- 3 August 2005
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (15) , 1118-1124
Open AccessHealth and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening
Background: Well-designed evaluations of health services are frequently made today. However, the extent of the evaluations' benefits and costs is not well documented, creating uncertainty whether their use is optimal from society's perspective. We examined these costs and benefits using data from one well-designed evaluation, the Quebec Neuroblastoma Screening Project (QNSP). It screened most Quebec newborns between 1989 and 1994 for neuroblastoma. As previously reported, the screening did not reduce neuroblastoma mortality and caused adverse health effects. Methods: We compared the cost of doing the QNSP with its benefits. Had the QNSP not been undertaken, neuroblastoma screening would have been implemented throughout North America. We assume that screening would have started in 1989 and ended in 2002. The QNSP's benefits include the health costs and adverse health effects averted by not using ineffective screening during those 14 years. In our calculations we used neuroblastoma incidence data for the QNSP and for Ontario where there was no screening, detailed data describing the health services used by the patients, and Quebec cost data for those services. Results: The QNSP cost $8.77 million (2002 US dollars). By not implementing similar screening programs between 1989 and 2002, the United States and Canada avoided $574.1 million in health costs, the unnecessary treatment of 9223 children, and false-positive findings for 5003 children screened. Conclusions: The health care costs and adverse health effects averted by the QNSP justify its costs. These results show that well-designed evaluations can yield—at least sometimes—benefits substantially greater than their high costs. This raises an important policy issue: are these evaluations now being under- or over used?